Belluscura plc, improving healthcare through innovation, in conjunction with its exclusive research partner Separation Design Group, announced today the recent filing of three patent applications and the notice of allowance of a fourth application in the fields of respiratory, postoperative recovery, sedation/sleep monitoring and artificial intelligence.
The latest patent application, titled “System and method for improving patient recovery postoperatively,” involves the combining of artificial intelligence and deep learning with Belluscura’s patented oxygen enrichment and sleep technology to improve patient postoperative recovery and reduce hospital readmission.
Belluscura now owns or exclusively licenses 15 patents and applications in the respiratory, sedation/sleep monitoring and artificial intelligence (AI) fields.
Commenting on the patenting activities, Bob Rauker, CEO of Belluscura, said: “We are very excited about our next generation technology.” “It is estimated that patient readmissions in the US alone cost Medicare $27bn per year.” “Incorporating AI into our leading-edge oxygen enrichment technology opens up additional markets in postoperative recovery beyond the current rapidly growing $1.2bn portable oxygen concentrator market.
This Press Release contains forward-looking statements that involve substantial risks and uncertainties, and actual results and developments may differ materially from those expressed or implied by these statements. These forward-looking statements are statements regarding the Company’s intentions, beliefs or current expectations concerning, among other things, the Company’s results of operations, financial condition, prospects, growth, strategies and the industry in which the Company operates. By their nature, forward-looking statements involve risks and uncertainties because they relate to events and depend on circumstances that may or may not occur in the future. These forward-looking statements speak only as of the date of this Press Release and the Company does not undertake any obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date of this Press Release.
Contact our Investor Relations team for more information.